All In Biotech

Drug Trial Radar · NCT07158918

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

A Multicenter, Open-label, Phase 1b/2 Trial of ABL103, a Bispecific Antibody of B7-H4 and 4-1BB, in Combination With Pembrolizumab With/Without Taxane in Subjects With Selected, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Aug 6, 2025

Primary completion

Dec 2, 2027

Study completion Dec 2, 2027

Sponsor

Lead sponsor
ABL Bio, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Sep 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

Conditions

  • Solid Tumors

Interventions

  • ABL103Drug

    IV infusion

  • KEYTRUDA® (pembrolizumab)Drug

    IV infusion

  • TaxaneDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: Day 1 to Day 21 (Safety Lead-in Part 1) and Day 1 to Day 28 (Safety Lead-in Part 2)
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs), Treatment-Related AEs, Serious AEs (SAEs), and Infusion-Related Reactions (IRRs)Time frame: From baseline through study completion, an average of 12 months
  3. Recommended Dose for Expansion (RDE) DeterminationTime frame: From baseline through study completion, an average of 12 months
  4. Objective Response Rate (ORR)Time frame: Up to approximately 30 months
  5. Disease Control Rate (DCR)Time frame: Up to approximately 30 months

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • UH Cleveland Medical Center

    Cleveland, Ohio · Not yet recruiting

  • PASO Medical

    Frankston, Victoria, Australia · Not yet recruiting

  • Seoul National University Bundang Hospital

    Seongnam, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Not yet recruiting

  • Samsung Medical Center

    Seoul, South Korea · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.